Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Rev Diabet Stud ; 14(1): 10-21, 2017.
Article in English | MEDLINE | ID: mdl-28632818

ABSTRACT

BACKGROUND: Pancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx. AIM: This study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate. METHODS: We analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls. RESULTS: Most of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients. CONCLUSION: This report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.


Subject(s)
Hypoglycemia/therapy , Islets of Langerhans Transplantation , Pancreas Transplantation , Adult , Blood Glucose/metabolism , C-Peptide/blood , Choice Behavior , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/etiology , Diabetes Mellitus, Type 1/therapy , Female , Follow-Up Studies , Graft Survival , Humans , Hypoglycemia/epidemiology , Islets of Langerhans Transplantation/adverse effects , Islets of Langerhans Transplantation/methods , Male , Middle Aged , Pancreas Transplantation/adverse effects , Pancreas Transplantation/methods , Retrospective Studies , Risk Assessment , Syndrome , Young Adult
2.
Cas Lek Cesk ; 155(7): 349-356, 2016.
Article in Czech | MEDLINE | ID: mdl-27990829

ABSTRACT

Islet transplantation (ITx) started in 2005 in IKEM as a potentially safer alternative to pancreas transplantation (PTx), which so far had represented the method of choice in type-1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. The aim of the study was to compare these two methods with regard to severe hypoglycemia elimination and to frequency of complications.Up to November 2015 a total number of 48 patients underwent ITx. The results from 22 patients with hypoglycemia unawareness were statistically analyzed. The mean number of transplanted islet equivalents was 12,096 (6,93316,705) IEQ/kg administered percutaneously in local anesthesia under radiological control to the portal vein. 44 patients underwent PTx from 1996. We evaluated glycated hemoglobin(HbA1c), insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia and complications. Medians (interquartile range) were analyzed using the Wilcoxon signed-rank test.One and two years after ITx, HbA1c decreased, C-peptide became significantly positive, insulin dose and frequency of severe hypoglycemia decreased and 18 % of ITx recipients were temporarily insulin-independent. Bleeding was present in 41 % of patients. One year after PTx, 73 % of patients were insulin and hypoglycemia-free, after two years 68 % of patients were insulin and hypoglycemia-free; graftectomy occurred in 20 % of recipients.Both methods led to restoration of insulin secretion and severe hypoglycemia elimination. PTx made more recipients insulin-independent at the cost of serious complications.


Subject(s)
Hypoglycemia/surgery , Islets of Langerhans Transplantation/methods , Pancreas Transplantation/methods , Adult , Female , Follow-Up Studies , Humans , Hypoglycemia/epidemiology , Islets of Langerhans Transplantation/statistics & numerical data , Male , Middle Aged , Pancreas Transplantation/statistics & numerical data , Pilot Projects , Postoperative Complications/epidemiology , Syndrome , Treatment Outcome
3.
Contrast Media Mol Imaging ; 7(6): 485-93, 2012.
Article in English | MEDLINE | ID: mdl-22991314

ABSTRACT

Labeling of pancreatic islets with superparamagnetic iron oxide (SPIO) nanoparticles enables their post-transplant monitoring by magnetic resonance imaging (MRI). Although the nanoparticles are incorporated into islet cells in culture, little is known about their fate in vivo. We studied the morphology of labeled islets after transplantation, aiming to identify the MRI contrast particles and their relationship to transplantation outcomes. Rat islets labeled with the ferucarbotran were transplanted into the liver or under the kidney capsule of syngeneic and allogeneic rats. After in vivo MRI, morphology was studied by light, fluorescence and transmission electron microscopy. Morphology of syngeneic islets transplanted beneath the kidney capsule vs into the liver was similar. Iron particles were almost completely eliminated from the endocrine cells and remained located in host-derived macrophages surrounding the vital islets for the entire study period. In the allogeneic model, islets lost their function and were completely rejected within nine days following transplantation in both transplant models. However, intercellular transport of the SPIO particles and subsequent MRI findings was different in the liver and kidney. In the liver, the decreasing number of islet-related MRI spots corresponded with clearance of iron particles in rejected islets; in contrast, with renal transplants extensive iron deposits with a high effect on MRI signal persisted in phagocytic cells beneath the capsule. We conclude that MRI detection of the iron contrast agent correlates with islet survival and function in islet transplantation into the liver, while it does not correlate in the case of transplantation beneath the renal capsule.


Subject(s)
Contrast Media/pharmacokinetics , Dextrans/pharmacokinetics , Animals , Contrast Media/chemistry , Dextrans/chemistry , Islets of Langerhans/cytology , Islets of Langerhans/metabolism , Islets of Langerhans Transplantation , Kidney/metabolism , Liver/metabolism , Magnetic Resonance Imaging , Magnetite Nanoparticles/chemistry , Male , Rats , Rats, Inbred Strains , Staining and Labeling , Tissue Distribution
4.
Contrast Media Mol Imaging ; 6(4): 308-13, 2011.
Article in English | MEDLINE | ID: mdl-21861290

ABSTRACT

The transplantation of pancreatic islets containing ß-cells, which produce insulin, is an alternative approach to the treatment of type 1 diabetes mellitus. The non-invasive visualization of transplanted islets can be performed using MRI; however, this requires labeling of the islets with a suitable contrast agent prior to transplantation. The detection of islets labeled by iron oxide-based contrast agents and transplanted into the liver tissue can be significantly improved using the intravenous administration of a suitable gadolinium contrast agent prior to MRI. The applied contrast agent not only improves the contrast-to-noise ratio, but also eliminates artifacts that may lead to an overestimation of the number of hypointense spots and their area; thus it improves the accuracy of automated and semi-automated procedures used for transplanted islet segmentation and quantification.


Subject(s)
Islets of Langerhans/cytology , Magnetic Resonance Imaging/methods , Animals , Contrast Media , In Vitro Techniques , Islets of Langerhans/metabolism , Islets of Langerhans Transplantation , Rats
5.
Cas Lek Cesk ; 150(1): 49-55, 2011.
Article in Czech | MEDLINE | ID: mdl-21404489

ABSTRACT

BACKGROUND: Organ pancreas transplantation represents the only method enabling long-term normalization of glucose metabolism in type-1 diabetic subjects so far. Unfortunately, surgical complications of this kind of therapy are still frequent. As a safer alternative, transplantation of isolated pancreatic islets was introduced at the Institute for Clinical and Experimental Medicine as a clinical experiment in the year 2005. METHODS AND RESULTS: We isolated the islets from pancreases of cadaveric donors which did not fulfil criteria to perform organ pancreas transplantation. Altogether, 36 islet implantations were performed in 28 C-peptide negative subjects suffering from type-1 diabetes by August 2010. In 15 subjects (21 implantations) the main indication was extremely instable course of diabetes due to the hypoglycaemia unawareness syndrome. In 5 and 3 cases, combined islet and kidney and islet and liver transplants were performed, respectively. In addition, islet autotransplantation was performed in 5 subjects undergoing total pancreatectomy. No patient died during the study period. In all but 1 patient with primary islet afunction, islet transplantation led to a complete cure of the hypoglycemia unawareness syndrome. Out of 15 patients, 11 subjects in this group showed a significant C-peptide production (> 0.2 pmol/ml) after 1 year. The mean insulin dose after allotransplantation decreased from 37 to 14 units per day and in 3 subjects, insulin therapy could be withdrawn. Serious technical complications occurred in 6 subjects, which only in 2 cases required surgical revision and did not cause long-term sequels. CONCLUSIONS: In comparison with organ pancreas transplantation, pancreatic islet transplantation represents a substantially safer method for restitution of endogenous insulin production. Though it eliminates serious hypoglycemic episodes in labile diabetes, complete insulin withdrawal is still often not possible. However, due to continuing progress in the laboratory techniques as well as in the transplant procedure itself, the results are steadily improving.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Islets of Langerhans Transplantation , Adult , Blood Glucose/analysis , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Female , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Islets of Langerhans Transplantation/adverse effects , Islets of Langerhans Transplantation/instrumentation , Islets of Langerhans Transplantation/methods , Male , Middle Aged
6.
Transplantation ; 85(1): 155-9, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-18192927

ABSTRACT

In vitro labeling of pancreatic islets with iron nanoparticles enables their direct posttransplant visualization by magnetic resonance; however, there is still a discrepancy in the fate of iron nanoparticles. This study was performed to detail the labeling process, consequently to improve the labeling efficacy and to confirm safety for islet cells. The islets were visible on T2*-weighted magnetic resonance images as hypointense spots immediately after 1-hr cultivation. Although at this time already the sufficient superparamagnetic effect was achieved, most of the particles were deposed in islet macrophages and only later were they found in endosomes of endocrine islet cells. The iron content depended on length of culture period. The labeled islets showed an intact ultrastructure, responded normally to glucose stimulation in vitro, and were able to treat experimental diabetes. For purpose of subsequent magnetic resonance imaging, a 24-hr culture with ferucarbotran leads to sufficient labeling with no apparent adverse effect on beta cell morphology or function.


Subject(s)
Ferric Compounds , Islets of Langerhans/pathology , Metal Nanoparticles , Animals , Cells, Cultured , Insulin-Secreting Cells/pathology , Islets of Langerhans Transplantation/methods , Macrophages/pathology , Magnetic Resonance Imaging/methods , Rats , Staining and Labeling/methods , Time Factors
7.
Autoimmunity ; 38(4): 319-23, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16206514

ABSTRACT

OBJECTIVE: A role of autoreactive T cells for type 1 diabetes pathogenesis is considered crucial. In our pilot study we addressed if autoreactive mononuclear cells are present also in peripheral blood of patients with other specific forms of diabetes as cystic fibrosis related diabetes (CFRD). METHODS: Cellular immune responses to a known beta-cell autoantigen (GAD65 and GAD65 derived peptides) were analysed by ELISPOT (IFN-gamma) and by protein microarray analysis in four patients suffering from CFRD, in four cystic fibrosis (CF) patients without diabetes, in eight type 1 diabetes patients (without CF) and in four healthy controls. RESULTS: Response to the autoantigen GAD65 (protein and peptides) was observed in 7/8 patients suffering from CF and in all type 1 diabetes patients. Post-stimulation production of Th1 cytokines (IFN-gamma, TNF-beta) was observed in 2/4 CFRD, 1/4 CF patients and in 7/8 type 1 diabetes patients. All these patients carry prodiabetogenic HLA-DQ genotype. Th2- and Th3 type of cytokine pattern was observed in 2/4 CF patients. Production of IL-8 was observed in the third CFRD as well as in the third CF patient and in 1/8 type 1 diabetes patient and borderline production of this chemokine was also observed in 2/4 healthy controls. No reaction was observed in the other 2/4 healthy controls and in the fourth CFRD patient who carried a strongly protective genotype and did not produce autoantibodies. The most potent peptide of GAD65 was amino acids 509-528. CONCLUSIONS: We consider our observations as a sign of a reaction directed against the self-antigen GAD65 that are closely connected to type 1 diabetes. In CF patients who do not develop diabetes autoreactive mechanisms are very probably efficiently suppressed by immune self-tolerance mechanisms. CFRD patients are a heterogenic group. To disclose those who may display features of autoimmune diabetes could have an impact for their therapy and prognosis.


Subject(s)
Autoantibodies/immunology , Cystic Fibrosis/complications , Diabetes Mellitus/immunology , Glutamate Decarboxylase/immunology , Isoenzymes/immunology , Leukocytes, Mononuclear/immunology , Adolescent , Adult , Autoantibodies/blood , Child , Cystic Fibrosis/immunology , Diabetes Mellitus/etiology , Female , HLA-DQ Antigens/immunology , Humans , Interferon-gamma/blood , Interleukin-8/blood , Lymphotoxin-alpha/blood , Male , Pilot Projects , Protein Array Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...